Evidence map›Paper›PMID 33566171›Full record

ArticleInflammation research : official journal of the European Histamine Research Society ... [et al.]2021

Therapeutic treatment of dietary docosahexaenoic acid for particle-induced pulmonary inflammation in Balb/c mice.

Paige Fletcher, Raymond F Hamilton, Joseph F Rhoderick, Britten Postma, Mary Buford, James J Pestka, Andrij Holian

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Paige FletcherDepartment of Biomedical and Pharmaceutical Sciences, Center for Environmental Health Sciences, University of Montana, 32 Campus Drive, Missoula, MT, 59812, USA. paige.fletcher@umontana.edu.ORCID http://orcid.org/0000-0001-6860-305X
Raymond F HamiltonDepartment of Biomedical and Pharmaceutical Sciences, Center for Environmental Health Sciences, University of Montana, 32 Campus Drive, Missoula, MT, 59812, USA.
Joseph F RhoderickDepartment of Biomedical and Pharmaceutical Sciences, Center for Environmental Health Sciences, University of Montana, 32 Campus Drive, Missoula, MT, 59812, USA.
Britten PostmaDepartment of Biomedical and Pharmaceutical Sciences, Center for Environmental Health Sciences, University of Montana, 32 Campus Drive, Missoula, MT, 59812, USA.
Mary BufordDepartment of Biomedical and Pharmaceutical Sciences, Center for Environmental Health Sciences, University of Montana, 32 Campus Drive, Missoula, MT, 59812, USA.
James J PestkaDepartment of Food Science and Human Nutrition, Institute for Integrative Toxicology, Michigan State University, East Lansing, MI, USA.
Andrij HolianDepartment of Biomedical and Pharmaceutical Sciences, Center for Environmental Health Sciences, University of Montana, 32 Campus Drive, Missoula, MT, 59812, USA.
Center for Environmental Health · USMichigan State University · US

Funding

Molecular Histology and Fluorescent ImagingP30GM103338 · NIGMS · UNIVERSITY OF MONTANA · PI ROBERTS, KEVAN · 2013 to 2017
$5.6M
Role of alveolar macrophage in omega-3 fatty acid amelioration of silica-triggered autoimmunity.R01ES027353 · NIEHS · MICHIGAN STATE UNIVERSITY · PI Andrew Olive · 2017 to 2026
$4.8M
Dietary DHA attenuation of nanoparticle inflammationR01ES023209 · NIEHS · UNIVERSITY OF MONTANA · PI HOLIAN, ANDRIJ · 2014 to 2018
$2.8M
Investigation of docosahexaenoic acid as a treatment for particle-induced inflammationF31ES028100 · NIEHS · UNIVERSITY OF MONTANA · PI FLETCHER, PAIGE · 2018 to 2020
$109k
NIEHS NIH HHS F31 ES028100NIEHS NIH HHS R01 ES023209NIEHS NIH HHS R01 ES027353NIGMS NIH HHS P30 GM103338
6 · The paper itself

Abstract

OBJECTIVE AND

designThe omega-3 polyunsaturated fatty acid docosahexaenoic acid (DHA) has been reported to suppress inflammation. Pulmonary inflammation can be directly linked to exposure of various occupational and man-made particles leading to pulmonary diseases. Therapeutic treatments are lacking for particle-induced pulmonary inflammation. These studies evaluated DHA as a therapeutic treatment for semi-acute and chronic particle-induced pulmonary inflammation.

methodsBalb/c mice were oropharyngeal instilled with hydrophobic multi-walled carbon nanotube (MWCNT) or hydrophilic crystalline silica (SiO

resultsDHA increased pulmonary inflammatory markers and lung pathology when mice were exposed to SiO

conclusionThe anti-inflammatory benefits of DHA treatment depend upon the type of inflammatory particle, magnitude of inflammation, and duration of treatment.

Indexed as

Dietary SupplementsAnimalsAnti-Inflammatory AgentsCells, CulturedCytokinesDocosahexaenoic AcidsFemaleInflammationLungLung DiseasesMacrophages, AlveolarMaleMiceMice, Inbred BALB CNanotubes, CarbonPhenotypeAnti-Inflammatory AgentsCytokinesDocosahexaenoic AcidsNanotubes, CarbonSilicon DioxideCrystalline silicaDocosahexaenoic acidMacrophage phenotypeMulti-walled carbon nanotubePhagolysosomal membrane damagePulmonary inflammation

Identifiers

PMID33566171
PMCPMC8127607
OpenAlexW3126385310

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.